Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, pharmaceuticals company AbbVie (NYSE:ABBV) has earned a coveted five-star ranking.

With that in mind, let's take a closer look at AbbVie and see what CAPS investors are saying about the stock right now.

AbbVie facts

Headquarters (founded)

North Chicago, Ill. (2012)

Market Cap

$58.3 billion 

Industry

Pharmaceuticals

Trailing-12-Month Revenue

$18.0 billion

Management

Chairman/CEO Richard Gonzalez
CFO William Chase

Trailing-12-Month Operating Margin

43.8%

Cash/Debt

$4.6 billion / $0

Dividend Yield

1.1%

Competitors

GlaxoSmithKline
Merck
Pfizer

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 98% of the 108 members who have rated AbbVie believe the stock will outperform the S&P 500 going forward.

Just yesterday, one of those Fools, czheng393, offered a cautiously bullish take on AbbVie:

(NYSE:ABT)

Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.